KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.

Haiyan Zhang, Zhiping Fan, Fen Huang, Lijie Han, Yajing Xu, Na Xu, Lan Deng, Shunqing Wang, Dongjun Lin, Xiaodan Luo, Qing Zhang, Xiaodan Liu, Xudong Li, Xinquan Liang, Shuangfeng Xie, Hong Qu, Sijian Yu, Hongsheng Zhou, Pengcheng Shi, Li Xuan, Ren Lin, Hui Liu, Hua Jin, Jing Sun, Qifa Liu

J Clin Oncol 41(2) 343-353

PMID36084276
PMCIDPMC9839269
DOI10.1200/JCO.22.00767
发表日期2022-09-09
入排依据:The record describes a Phase III randomized trial in oncology with a time-to-event primary endpoint (OS). However, the intervention compares a drug-containing regimen (BuCy) to a regimen that includes total body irradiation (TBI-Cy), which is not a drug-containing intervention in both arms. The requirement specifies 'a drug-containing intervention' for both arms in the comparison. Therefore, it is excluded due to insufficient drug intervention evidence for the primary comparison.
摘要

摘要

PURPOSE: It remains controversial whether busulfan-based versus total body irradiation (TBI)-based regimens have comparable outcomes in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). We investigated the efficacy and toxicity of busulfan plus cyclophosphamide (BuCy) and TBI plus cyclophosphamide (TBI-Cy) conditioning in allo-HSCT for adult standard-risk B-cell-ALL in first complete remission (CR1). PATIENTS AND METHODS: We performed an open-label, randomized phase III trial at 13 hospitals in China. Eligible patients (age 14-65 years) had standard-risk ALL in CR1. Patients were randomly assigned (1:1) to BuCy (0.8 mg/kg four times per day on days -7 to -4 and cyclophosphamide 60 mg/kg once daily on days -3 to -2) or TBI-Cy (4.5 Gy TBI on days -5 to -4 and cyclophosphamide 60 mg/kg once daily on days -3 to -2). The primary end point was 2-year overall survival. Analysis was per protocol. This trial is registered with ClinicalTrials.gov (identifier: NCT02670252) and is complete. RESULTS: Between January 2016 and February 2020, 275 patients were assigned to receive BuCy (273 assessed) and 275 to TBI-Cy (272 assessed). The 2-year overall survival was 76.6% (95% CI, 71.7 to 81.8) and 79.4% (74.7 to 84.4; P = .457; difference 2.9%; 95% CI, -4.1 to 9.8; P = .022), indicating noninferiority of BuCy. The 2-year relapse was 20.2% (95% CI, 15.6 to 25.1) and 18.4% (14.0 to 23.2; P = .616), and the nonrelapse mortality was 11.0% (95% CI, 7.6 to 15.0) and 11.0% (7.7 to 15.1; P = .988) in the BuCy and TBI-Cy groups, respectively. There were no differences in regimen-related toxicity, graft-versus-host disease, or late effects between the two groups. CONCLUSION: The BuCy regimen has noninferior efficiency and safety as TBI-Cy (4.5 Gy × 2) for patients with adult standard-risk B cell-ALL in CR1 undergoing HLA-matched allo-HSCT.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。